Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heart failure associated with minoxidil intoxication in a cat.

Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2025
Same author

Prevalence of sacroiliitis on magnetic resonance enterography in Crohn's disease and its association with intestinal findings: a monocentric observational cross-sectional study.

Clinical and experimental medicine·2025
Same author

Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease.

Autoimmunity reviews·2025
Same author

Sjögren's syndrome and pulmonary hypertension: Exploring the intricate link with interstitial lung disease.

International journal of cardiology·2025
Same author

Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: A multicentre study.

Multiple sclerosis and related disorders·2024
Same author

A rare case of symptomatic creatine kinase elevation in a patient with rheumatoid arthritis treated with baricitinib.

Reumatismo·2024

Related Experiment Video

Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Cardiovascular risk and prostanoids in systemic sclerosis.

M Colaci1, M Sebastiani, D Giuggioli

  • 1Chair and Rheumatology Unit, University of Modena e Reggio Emilia, Medical School; Policlinico di Modena, Modena, Italy.

Clinical and Experimental Rheumatology
|June 21, 2008
PubMed
Summary

Intravenous prostanoid therapy for systemic sclerosis (SSc) may increase cardiovascular ischemic event risk, particularly in high-risk patients. Careful cardiovascular evaluation is crucial before initiating prostanoid treatment for severe scleroderma complications.

Related Experiment Videos

Last Updated: Jul 4, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Cardiology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic sclerosis (SSc) frequently involves Raynaud's phenomenon and cutaneous ulcers.
  • Intravenous (IV) prostanoids are used for SSc patients resistant to oral treatments.
  • Anecdotal reports suggest a potential cardiovascular ischemic risk with prostanoid therapy in SSc.

Purpose of the Study:

  • To evaluate the cardiovascular risk and incidence of ischemic events in SSc patients undergoing long-term prostanoid therapy.
  • To compare these events with a control group receiving only oral medications.

Main Methods:

  • Retrospective evaluation of 50 SSc patients on long-term prostanoid therapy (iloprost or alprostadil).
  • Comparison with 42 SSc control patients treated solely with oral drugs.
  • Assessment of cardiovascular risk factors and incidence of myocardial infarction or stroke.

Main Results:

  • Ischemic cardiovascular complications occurred significantly more often in prostanoid-treated patients (14%) versus controls (2.4%; p=0.041).
  • In patients with high cardiovascular risk, events were significantly more frequent in the prostanoid group (60%) compared to controls (5.2%; p=0.0026).

Conclusions:

  • Prostanoid treatment may play a role in the pathogenesis of ischemic cardiovascular complications in SSc patients with high cardiovascular risk.
  • Prostanoids are a first-line treatment for severe scleroderma ischemic cutaneous lesions.
  • Thorough cardiovascular risk assessment is essential before initiating prostanoid therapy in SSc patients.